Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events

BACKGROUND: The clear evidence of cardiovascular benefits in cardiovascular outcome trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes might suggest an effect on atherosclerotic plaque vulnerability and/or thrombosis, in which myeloid angiogenic cells (MAC) and platelets...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cardiovasc Diabetol
Asıl Yazarlar: Spigoni, Valentina, Fantuzzi, Federica, Carubbi, Cecilia, Pozzi, Giulia, Masselli, Elena, Gobbi, Giuliana, Solini, Anna, Bonadonna, Riccardo C., Dei Cas, Alessandra
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140327/
https://ncbi.nlm.nih.gov/pubmed/32264868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01016-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller